Results 161 to 170 of about 3,867 (204)

Piracetam in chronic brain failure

Current Medical Research and Opinion, 1979
A double-blind, placebo-controlled trial was carried out on 109 aged patients with minimal or with moderate chronic brain failure to assess the effectiveness of piracetam (2.4 g per day) in preventing the progression of dementia. Patients received piracetam or placebo each for 6 weeks, the order of treatment being at random.
S, Lloyd-Evans, J C, Brocklehurst, M K, Palmer   +2 more
openaire   +2 more sources

DFT computational analysis of piracetam

Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2014
Density functional theory calculation with B3LYP using 6-31G(d,p) and 6-31++G(d,p) basis set have been used to determine ground state molecular geometries. The first order hyperpolarizability (β0) and related properties (β, α0 and Δα) of piracetam is calculated using B3LYP/6-31G(d,p) method on the finite-field approach.
P, Rajesh, S, Gunasekaran, S, Seshadri, T, Gnanasambandan   +3 more
openaire   +2 more sources

Piracetam for dementia or cognitive impairment

Cochrane Database of Systematic Reviews, 2004
To determine the clinical efficacy of piracetam for the features of dementia or cognitive impairment, classified according to the major subtypes of dementia: vascular, Alzheimer's disease or mixed vascular and Alzheimer's disease, or unclassified dementia, or cognitive impairment not fulfilling the criteria for dementia.The trials were identified from ...
L, Flicker, J, Grimley Evans
openaire   +3 more sources

The Effectiveness of Piracetam in Vertigo

Pharmacopsychiatry, 1999
Vertigo is a sensation of altered orientation in space and may be defined as an illusion of movement. It is a subjective symptom and therefore difficult to assess. Examination and diagnosis remain difficult. Although treatment should be directed at the underlying cause or disorder, the origin of vertigo is frequently unknown or untreatable ...
openaire   +2 more sources

The Effects of Piracetam in Children with Dyslexia

Journal of Clinical Psychopharmacology, 1985
Following previous research which suggests that piracetam improves performance on tasks associated with the left hemisphere, a 12-week, double-blind, placebo-controlled study of developmental dyslexics was conducted. Six study sites treated 257 dyslexic boys between the ages of 8 and 13 years who were significantly below their potential in reading ...
MARK DI IANNI, COLIN R. WILSHER, MARION S. BLANK, C KEITH CONNERS, CHRISTOPHER H. CHASE, H HARRIS FUNKENSTEIN, ELAYNE HELFGOTT, JANE M. HOLMES, LORRAINE LOUGEE, GABE JOSEPH MALETTA, JANET MILEWSKI, FRANCIS J. PIROZZOLO, RITA G. RUDEL, PAULA TALLAL   +13 more
openaire   +2 more sources

Piracetam in the Treatment of Cortical Myoclonus

Pharmacopsychiatry, 1999
This paper reviews existing publications on the use of piracetam for the treatment of cortical myoclonus of various etiologies and includes the personal experience of the authors in progressive myoclonus epilepsy. Two double-blind comparisons with placebo provided results which allow recommendations for the dosage and usage of piracetam in cortical ...
P, Genton, R, Guerrini, C, Remy
openaire   +2 more sources

Piracetam

2010
Otto Benkert, Ion Anghelescu, Christoph Fehr, Gerhard Gründer, Philip Heiser, Christoph Hiemke, Christian Lange-Asschenfeldt, M. J. Müller, M. Paulzen, Francesca Regen, Axel Steiger   +10 more
  +4 more sources

Piracetam

Reactions Weekly, 2022
openaire   +1 more source

Effects of Piracetam on developmental dyslexia

International Journal of Psychophysiology, 1986
A new class of drugs (nootropics) are viewed from the perspective of their neuropsychological effect upon developmental dyslexia. Evidence from both the preclinical and clinical work conducted on Piracetam is briefly reviewed. The latest research on the effects of Piracetam in dyslexia shows a convergence of results. Attempts to replicate these results
openaire   +2 more sources

Piracetam

Reactions Weekly, 2015
openaire   +2 more sources